A Phase 2 interventional study of Antistax®, low dose and Antistax®, high dose in Venous Insufficiency, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 25 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-07-16.
Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment
Study to determine the efficacy and tolerability of two dose levels of Antistax relative to placebo in patients suffering from CVI grade I or incipient grade II
189 studies on the registry are indexed under Venous Insufficiency; 16 are open to participants now.
This study's enrollment of 260 is above the median of 60 across 139 interventional studies indexed under Venous Insufficiency.
Browse Venous Insufficiency studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Concomitant disease(s) exclusion criteria:
Previous treatment(s) exclusion criteria:
Concomitant treatment/non-drug therapy exclusion criteria:
Other exclusion criteria:
Drug: Antistax®, low dose
Drug: Antistax®, high dose
Drug: Placebo
Changes from baseline of limb volume
determined by water displacement
Time frame: Baseline, day 84
Changes of limb volume
determined by water displacement
Time frame: Baseline, days 42 and 98
Measurement of calf circumference
in centimeters
Time frame: Baseline, days 42, 84 and 98
Measurement of ankle circumference
in centimeters
Time frame: Baseline, days 42, 84 and 98
Assessment of subjective symptoms on a visual analogue scale (VAS)
Time frame: Baseline, days 42, 84 and 98
Assessment of global efficacy by patient on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
Assessment of global efficacy by investigator on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
Assessment of global tolerability by patient on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
Assessment of global tolerability by investigator on a 4-point verbal rating scale
Time frame: days 42, 84 and 98
Number of patients with adverse events
Time frame: up to 14 weeks
No study locations are listed for this record.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim